An investment theme focused on prioritizing the allocation of management resources to the Japanese operations, prompted by the decision to divest the U.S. business, in order to resolve quality issues in Japan and respond to growing demand. This includes increasing production by 2.5 billion tablets through capital investment in the Seima No. 2 and No. 3 plants.